Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort

Benign breast disease (BBD) is an established breast cancer (BC) risk factor, but it is unclear whether the magnitude of the association applies to women at familial or genetic risk. This information is needed to improve BC risk assessment in clinical settings. Using the Prospective Family Study Cohort, we used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of BBD with BC risk. We also examined whether the association with BBD differed by underlying familial risk profile (FRP), calculated using absolute risk estimates from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model. During 176,756 person‐years of follow‐up (median: 10.9 years, maximum: 23.7) of 17,154 women unaffected with BC at baseline, we observed 968 incident cases of BC. A total of 4,704 (27%) women reported a history of BBD diagnosis at baseline. A history of BBD was associated with a greater risk of BC: HR = 1.31 (95% CI: 1.14–1.50), and did not differ by underlying FRP, with HRs of 1.35 (95% CI: 1.11–1.65), 1.26 (95% CI: 1.00–1.60), and 1.40 (95% CI: 1.01–1.93), for categories of full‐lifetime BOADICEA score <20%, 20 to <35%, ≥35%, respectively. There was no difference in the association for women with BRCA1 mutations (HR: 1.64; 95% CI: 1.04–2.58), women with BRCA2 mutations (HR: 1.34; 95% CI: 0.78–2.3) or for women without a known BRCA1 or BRCA2 mutation (HR: 1.31; 95% CI: 1.13–1.53) (pinteraction = 0.95). Women with a history of BBD have an increased risk of BC that is independent of, and multiplies, their underlying familial and genetic risk.

[1]  R. Vierkant,et al.  Evaluation of 2 breast cancer risk models in a benign breast disease cohort , 2018, Cancer.

[2]  R. Vierkant,et al.  Clinicopathologic features of breast cancers that develop in women with previous benign breast disease , 2016, Cancer.

[3]  J. Cuzick,et al.  Impact of preventive therapy on the risk of breast cancer among women with benign breast disease , 2015, Breast.

[4]  A. Whittemore,et al.  Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) , 2015, International journal of epidemiology.

[5]  G. Colditz,et al.  Breast cancer risk associated with benign breast disease: systematic review and meta-analysis , 2015, Breast Cancer Research and Treatment.

[6]  D. Easton,et al.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.

[7]  Abdissa Negassa,et al.  A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer , 2010, Cancer Causes & Control.

[8]  A. Whittemore,et al.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research , 2009, Breast Cancer Research and Treatment.

[9]  H A Risch,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[10]  R. Vierkant,et al.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Judith Abrams,et al.  Breast Cancer Incidence in a Cohort of Women with Benign Breast Disease from a Multiethnic, Primary Health Care Population , 2007, The breast journal.

[12]  G. Colditz,et al.  The influence of family history on breast cancer risk in women with biopsy‐confirmed benign breast disease , 2006, Cancer.

[13]  R. Vierkant,et al.  An Analysis of Breast Cancer Risk in Women With Single, Multiple, and Atypical Papilloma , 2006, The American journal of surgical pathology.

[14]  John L Hopper,et al.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.

[15]  V Shane Pankratz,et al.  Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.

[16]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[17]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[18]  A. Ellis Breast , 2002, BMJ : British Medical Journal.

[19]  J. Sloane,et al.  Histopathologic Types of Benign Breast Lesions and the Risk of Breast Cancer: Case–Control Study , 2002, The American journal of surgical pathology.

[20]  R. Osborne,et al.  kConFab: a research resource of Australasian breast cancer families , 2000, The Medical journal of Australia.

[21]  N. Ohuchi,et al.  Risk of Breast Cancer in Japanese Women with Benign Breast Disease , 1999, Japanese journal of cancer research : Gann.

[22]  C. Bodian,et al.  Prognostic significance of benign proliferative breast disease , 1993, Cancer.

[23]  L. Brinton,et al.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.

[24]  P. Wingo,et al.  Histologic types of benign breast disease and the risk for breast cancer , 1992, Cancer.

[25]  G. Colditz,et al.  A prospective study of benign breast disease and the risk of breast cancer , 1992, JAMA.

[26]  P. Taylor,et al.  A prospective study of the development of breast cancer in 16,692 women with benign breast disease. , 1988, American journal of epidemiology.

[27]  W. Dupont,et al.  Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. , 1987, American journal of epidemiology.

[28]  W. Dupont,et al.  Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .

[29]  David L. Page,et al.  Atypical hyperplastic lesions of the female breast. A long‐term follow‐up study , 1985, Cancer.

[30]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[31]  L. Hartmann,et al.  Atypical hyperplasia of the breast--risk assessment and management options. , 2015, The New England journal of medicine.

[32]  G. Colditz,et al.  Genetic variation and circulating levels of IGF‐I and IGFBP‐3 in relation to risk of proliferative benign breast disease , 2010, International journal of cancer.

[33]  M. Silverstein Where's the outrage? , 2009, Journal of the American College of Surgeons.

[34]  J. Hopper,et al.  Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort , 2004, Familial Cancer.